Edarbi is an anti-hypertensive drug owned by Azurity. This drug, which contains the active ingredient azilsartan kamedoxomil, was first authorized for market use on February 25, 2011. Edarbi is available in tablet form for oral administration. Currently, Edarbi holds three patents, none of which have yet expired.
The generic version of Edarbi is estimated to become available after March 26, 2028. This is predicated on the expiry of Edarbi's last held patent on this date.
Edarbi, with its active ingredient azilsartan kamedoxomil, is primarily used as a treatment for hypertension. azilsartan kamedoxomil is effective in reducing blood pressure, thereby aiding in the management of hypertension.
Edarbi currently holds three patents, with the last one set to expire on March 26, 2028. This patent, US9066936, involves a Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent. Below are the details of the patent: